European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has announced their approval of diroximel fumarate (Vumerity, Biogen Inc) for adults diagnosed with relapsing-remitting multiple sclerosis (MS). Although Diroximel fumarate is comparable to dimethyl fumarate (Tecfidera, Biogen Inc) in effectiveness, the drug does have a unique chemical structure that less likely to induce strong irritation in the gastrointestinal (GI) tract, as shown in the EVOLVE-MS-2 clinical trial. The backing will now be reviewed by the European Commission. Diroximel fumarate has already been approved by the US FDA (Food and Drug Administration) for MS.
Read more here.